Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $74.86 Consensus PT from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have received an average rating of “Buy” from the ten ratings firms that are presently covering the company, MarketBeat reports. Ten investment analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued a report on the stock in the last year is $74.86.

JSPR has been the subject of several recent analyst reports. Evercore ISI restated an “outperform” rating and set a $65.00 target price on shares of Jasper Therapeutics in a research note on Monday, August 26th. JMP Securities reiterated a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Stifel Nicolaus assumed coverage on Jasper Therapeutics in a research note on Thursday, June 27th. They issued a “buy” rating and a $86.00 target price for the company. Finally, Royal Bank of Canada decreased their price target on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 14th.

Jasper Therapeutics Stock Performance

Shares of JSPR stock opened at $20.04 on Friday. The stock’s 50 day simple moving average is $19.18 and its 200 day simple moving average is $21.35. Jasper Therapeutics has a twelve month low of $4.00 and a twelve month high of $31.01. The company has a market capitalization of $301.88 million, a price-to-earnings ratio of -3.56 and a beta of 2.21.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.12. On average, analysts forecast that Jasper Therapeutics will post -4.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

Several large investors have recently made changes to their positions in JSPR. Wolff Wiese Magana LLC bought a new position in Jasper Therapeutics during the 3rd quarter valued at about $59,000. Rhumbline Advisers acquired a new stake in shares of Jasper Therapeutics during the second quarter worth approximately $300,000. Virtu Financial LLC bought a new position in shares of Jasper Therapeutics in the first quarter valued at approximately $306,000. American Century Companies Inc. raised its stake in shares of Jasper Therapeutics by 27.1% in the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after acquiring an additional 3,032 shares during the last quarter. Finally, Concurrent Investment Advisors LLC acquired a new position in shares of Jasper Therapeutics in the 1st quarter worth approximately $599,000. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.